A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia; Chemotherapy-induced damage
- Focus Therapeutic Use
- 06 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 06 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 10 Mar 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2023.